Overview

Investigating Chinese Herbal Medicine for Modulating Gut Microbiota in Treating Inflammatory Bowel Disease: Molecular Mechanisms and Clinical Study

Status:
COMPLETED

Trial end date:
2025-06-06

Target enrollment:

Participant gender:

Summary

The goal of this exploratory, single-arm intervention study is to evaluate whether Banxia Xiexin Decoction (BXD) can prevent colitis by modulating gut microbiota composition and regulating immune responses, including IgA production, in healthy adults. The main questions it aims to answer are: Can BXD prevent colitis by modulating gut microbiota composition? Can BXD enhance immune markers such as IgA without adverse effects? There is no comparison group in this study. Participants will: Take BXD daily for 14 days. Provide stool and blood samples for microbiota analysis and immune marker testing. Eligible participants include healthy men and women aged 20 years or older, with no major illnesses, autoimmune diseases, cancer, or recent use of antibiotics, immunosuppressants, or probiotics.

Phase:

Details

Lead Sponsor:

China Medical University Hospital